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Background: Analysis of key therapeutic targets such as epidermal growth factor receptor (EGFR) in clinical tissue
samples is typically done by immunohistochemistry (IHC) and is only subjectively quantitative through a narrow
dynamic range. The development of a standardized, highly-sensitive, linear, and quantitative assay for EGFR for use
in patient tumor tissue carries high potential for identifying those patients most likely to benefit from EGFR-targeted
therapies.
Methods: A mass spectrometry-based Selected Reaction Monitoring (SRM) assay for the EGFR protein (EGFR-SRM)
was developed utilizing the Liquid Tissue®-SRM technology platform. Tissue culture cells (n = 4) were analyzed by
enzyme-linked immunosorbent assay (ELISA) to establish quantitative EGFR levels. Matching formalin fixed cultures
were analyzed by the EGFR-SRM assay and benchmarked against immunoassay of the non-fixed cultured cells.
Xenograft human tumor tissue (n = 10) of non-small cell lung cancer (NSCLC) origin and NSCLC patient tumor tissue
samples (n = 23) were microdissected and the EGFR-SRM assay performed on Liquid Tissue lysates prepared from
microdissected tissue. Quantitative curves and linear regression curves for correlation between immunoassay and
SRM methodology were developed in Excel.
Results: The assay was developed for quantitation of a single EGFR tryptic peptide for use in FFPE patient tissue
with absolute specificity to uniquely distinguish EGFR from all other proteins including the receptor tyrosine kinases,
IGF-1R, cMet, Her2, Her3, and Her4. The assay was analytically validated against a collection of tissue culture cell
lines where SRM analysis of the formalin fixed cells accurately reflects EGFR protein levels in matching non-formalin
fixed cultures as established by ELISA sandwich immunoassay (R2 = 0.9991). The SRM assay was applied to a
collection of FFPE NSCLC xenograft tumors where SRM data range from 305amol/μg to 12,860amol/μg and are
consistent with EGFR protein levels in these tumors as previously-reported by western blot and SRM analysis of the
matched frozen tissue. In addition, the SRM assay was applied to a collection of histologically-characterized FFPE
NSCLC patient tumor tissue where EGFR levels were quantitated from not detected (ND) to 670amol/μg.
Conclusions: This report describes and evaluates the performance of a robust and reproducible SRM assay
designed for measuring EGFR directly in FFPE patient tumor tissue with accuracy at extremely low (attomolar) levels.
This assay can be used as part of a complementary or companion diagnostic strategy to support novel therapies
currently under development and demonstrates the potential to identify candidates for EGFR-inhibitor therapy,* Correspondence: d.krizman@expressionpathology.com
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Many human cancers are associated with over-expressed
epidermal growth factor receptor (EGFR) [1]. EGFR is a
validated, potential therapeutic target in many human can-
cers including colorectal, ovarian, head and neck, bladder,
lung, pancreatic, and breast. Over-expression and/or
activation of EGFR by ligand are associated with activation
of several cytoplasmic proteins that induce a signal that
stimulates intracellular responses and activation of signal-
ing pathway proteins in the RAS/RAF/MAPK, STAT and
PI3K/AKT pathways, which together modulate cellular
proliferation, adhesion, angiogenesis, migration, and sur-
vival [2,3]. Cellular EGFR activity is a product of complex
factors including expression level, ligands, mutation,
dimerization-regulated conformation. Analysis of EGFR at
the protein level, however, in clinical tissue samples (with
respect to patient tumor profiling and targeted therapy) is
typically done by immunohistochemistry (IHC) that is only
subjectively quantitative through a narrow dynamic range.
EGFR-directed antibodies (cetuximab and panitumumab)
and small molecule inhibitors (gefitinib and erlotinib) pro-
vide positive therapeutic effects in several types of cancer,
including non-small cell lung cancer (NSCLC). Clinical
data show that EGFR expression levels as currently deter-
mined by IHC historically do not predict clinical outcome
in response to anti-EGFR targeted therapy [4,5]. However,
recent reports suggest EGFR protein levels may provide
some predictive response data to gefitinib and cetuximab in
NSCLC patients but that the choice of diagnostic antibody
and IHC methodology is paramount to predicting response
and outcome to specific therapies [6,7]. These reports
suggest that measuring EGFR in patient tissue may indeed
correlate to therapeutic outcome, yet it is clear that applica-
tion of alternative, robust, reproducible, and scalable tech-
nologies for conclusive objective quantitation of the EGFR
protein is required to predict and improve therapeutic out-
comes through more optimal patient selection, monitoring,
and dosing.
Mass spectrometry (MS) has emerged as a method to
quantitatively analyze proteins in biological samples, and
application of MS to patient-derived tissue could have a
large, positive impact on patient stratification and targeted
cancer therapeutics [8-12]. The Liquid Tissue-SRM
technology platform is based on application of mass spec-
trometry to solubilized protein lysates from formalin fixed,
paraffin embedded (FFPE) patient-derived tissue [13-20].
This report demonstrates development of a robust, repro-
ducible Liquid Tissue-SRM assay capable of conclusivelymeasuring EGFR protein levels in Liquid Tissue lysates pre-
pared from formalin fixed samples including patient-derived
FFPE tumor tissue. Clinical application of this assay could
provide for patient selection to optimize EGFR-targeted
therapy strategies, predict patient outcome, and determine
the potential for therapeutic resistance to other receptor
tyrosine kinase inhibitor molecules.
Materials and Methods
Cell lines
Four human cell lines, A431 (skin), HT29 (colon), MDA-
MB-231 (breast), and MCF7 (breast) were utilized for this
study. A431 and MDA-MB-231 lines were maintained in
Dulbecco’s Modified Eagle Medium (DMEM), HT29 cells
were maintained in McCoy’s5A medium, and MCF7 cells
were maintained in DMEM-F12. All media were supple-
mented with 10 % fetal bovine serum (FBS) and antibiotics.
Each cell line was grown in sufficient quantity so that pre-
parations of each cell line could be processed in parallel for
both ELISA and SRM analysis.
Formalin fixed paraffin embedded (FFPE) culture cells
were prepared by pelleting cell suspensions, overlaying the
pellet with 10 % neutral-buffered formalin (NBF), and
allowing the cells to fix for 18 to 24 hours at 4°C. The 10 %
formalin was removed and the pellet was washed with water
and then transferred into 70 % ethanol. Embedding in
paraffin and sectioning of cells prepared on microscope
slides were done using standard histology methods.
Tissue and tissue microdissection
Ten (10) human xenograft FFPE tumor blocks of non-small
cell lung carcinoma (NSCLC) origin were obtained from a
collection of xenograft tumors previously described [21].
Twenty-three (23) FFPE NSCLC patient tissue blocks were
obtained without patient identifiers from the University of
Toronto Princess Margaret Hospital/University Health
Network with informed consent of all participating subjects
under strict Institutional Review Board (IRB) standards and
Ethical Committee approval. All patients were participants
in a phase II clinical trial where they received neoadjuvant
treatment with the EGFR-inhibitor gefitinib prior to surgical
resection of their tumor [22]. Histological analysis indicates
a mixture of adenocarcinoma, squamous cell carcinoma,
and one large cell carcinoma in the cohort. Multiple ten mi-
cron (10 μm) thick sections from each of the FFPE cell line
blocks, FFPE NSCLC xenograft tumor blocks, and the FFPE
NSCLC patient tissue blocks were cut onto DIRECTOR®
slides for tissue microdissection according to manufacturer’s
Hembrough et al. Clinical Proteomics 2012, 9:5 Page 3 of 10
http://www.clinicalproteomicsjournal.com/content/9/1/5recommendations (Onco Plex Diagnostics Inc. Rockville,
MD).
DIRECTOR slides with sectioned FFPE cultured cells,
xenograft tumor tissue, and patient tumor tissue were
deparaffinized and stained with hematoxylin using standard
histological methods prior to dissection. Microdissection
was performed on a Leica LMD6000 dissection scope
according to manufacturer’s recommendations (Leica,
Wetzlar, Germany). A total area of 12 mm2 consisting of
approximately 45,000 formalin fixed cultured cells or tissue-
derived cancerous cells were transferred from the FFPE sec-
tions via laser dissection directly into the dry cap of a 0.5 ml
tube. Once the entire 12 mm2 area was transferred to the
dry cap, 20ɥl of 100 % acetonitrile (ACN) was added to the
cap and the cell/tissue material was transferred to the
bottom of the tube by a brief centrifugation. The ACN was
removed by speedvac centrifugation at 35°C for 6 min. The
dried dissection pellet was stored at −20°C.
Sample preparation and immunoassay
Protein lysates of fresh, unfixed cells for each culture cell
line were prepared for analysis by enzyme-linked immuno-
sorbent assay (ELISA) using the manufacturer-provided cell
lysis buffer and protocol according to manufacturer’s
recommendations (Millipore, Billerica, MA). Adherent cells
were washed twice in the flask with ice-cold PBS and all the
PBS was drained. Ice-cold lysis buffer (modified RIPA
buffer) was added to the cells (1 mL per 107 cells/100 mm
dish/150 cm2 flask). Cells were scraped off the flask with a
plastic cell scraper and the cell suspension was transferred
to a centrifuge tube where the suspension was gently rocked
on an orbital shaker 15 min to lyse cells. The lysate was
centrifuged at 14,000 g for 15 min and the supernatant was
transferred to a fresh centrifuge tube. The pellet was
discarded. Total protein content was determined by a Micro
BCA assay according to manufacturer’s recommendations
(Thermo Fisher Scientific Inc, Rockford, IL). The lysate was
divided into aliquots and stored at −20°C. EGFR levels were
determined by ELISA-based sandwich immunoassay utiliz-
ing an ELISA kit according to manufacturer’s recommenda-
tions (Millipore, Billerica, MA). ELISA immunoassay was
performed on each protein lysate in triplicate and data
collected on a μQuant plate reader (Bio-Tek Instruments,
Winooski, VT).
SRM assay development
Recombinant EGFR protein was obtained and analyzed on
an Orbitrap mass spectrometer (Thermo Scientific, San
Jose, CA) equipped with a nanoAcquityLC system (Waters,
Milford, MA) and on a TSQVantage triplequadrupole mass
spectrometer (Thermo Scientific, San Jose, CA) equipped
with a nanoAcquityLC to evaluate all tryptic peptides in
order to identify candidate SRM peptides. Liquid Tissue
lysates prepared from FFPE A431 cells were analyzed onthe TSQVantage system. Software programs Pinpoint1.0,
Xcalibur2.1 (Thermo Scientific, San Jose, CA) were used to
identify optimal tryptic peptides based on reproducible peak
heights, retention times, chromatographic ion intensities,
and distinctive/reproducible transition ion ratios. Methio-
nine and cysteine-containing peptides were excluded due to
the existence of various oxidation entities. Peptides with gly-
cosylation motifs were also excluded. The uniqueness of
observed peptides was verified by performing a peptide se-
quence search using the BLASTP function of the BLAST
search engine (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and a
single peptide unique to EGFR was chosen which spans
residues 98–108 of the EGFR extracellular domain. Un-
labeled (IPLENLQIIR) and isotopically-labeled (IPLEN
[13CN15]LQIIR) versions of this peptide were synthesized
to develop and perform the assay (Thermo Scientific, San
Jose, CA). SRM transitions used for the quantification of
EGFR using unlabeled peptide were 604.872/756.472 (y6+1),
885.515 (y7+1), 998.599 (y8+1) (Q1/Q3); and transitions used
for quantitation of EGFR using isotopically labeled peptide
608.36/763.489 (y6+1), 892.532 (y7+1), 1005.616 (y8+1) (Q1/
Q3).
A standard curve was developed by serial dilution of the
light peptide against a constant concentration of labeled
peptide in a non-human complex tryptic peptide mixture
from Pyrococcus furiosus (P. furiosus) (Agilent Technologies
Inc, Santa Clara, CA) on the TSQVantage system utilizing
the following conditions; Q1(FWHM);0.2, Q2(FWHM):0.7,
dwell time;10 ms. Due to non-availability of a “standard tis-
sue matrix” for development of a standard curve, the P.
furiosus matrix was used as a simulation of the matrix that
exists in the tissue environment. Data was analyzed by
Pinpoint1.0 to determine the limit of detection (LOD) and
limit of quantitation (LOQ). The LOD was determined by
identifying the lowest concentration in the standard curve
where the transition ion ratios and co-elution profile of the
unlabeled synthetic peptide were similar to labeled synthetic
peptide. Additionally, a signal to noise ratio >3 and a CV
from triplicate measurements ≤25 % were used. The LOQ
was determined by identifying the next highest concentra-
tion of the standard curve above the LOD with a CV ≤ 25 %
and signal to noise ratio >10.
Sample preparation and SRM analysis
Liquid Tissue lysates were prepared for SRM analysis
using the Liquid Tissue preparation protocol and
reagents according to manufacturer’s recommendations
(Onco Plex Diagnostics Inc. Rockville, MD) for each of
the microdissected FFPE cell lines and FFPE tissue sam-
ples. Briefly, dried microdissection pellets were sus-
pended in 30 μl of Liquid Tissue buffer and heated at 95°
C for 90 min with gentle agitation every 20 min followed
by cooling on ice at which point 1.5 μl of trypsin (1 μg/
μl) was added to each tube. Tubes were incubated at
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stored at −20°C. Total protein content for each Liquid
Tissue lysate was determined by a Micro BCA assay
(Thermo Fisher Scientific Inc, Rockford, IL).
For analysis of Liquid Tissue lysates from both microdis-
sected FFPE cultured cells and FFPE microdissected patient
tissue, 5 μg of Liquid Tissue lysate was diluted to 45 μl with
0.1 % formic acid, and then 5 μl of the isotopically labeled
internal standard peptide (5fmol/μl) was added. Following a
centrifugation step at 10,000 x g for 10 min, 45 μl of each
supernatant was placed in the TSQ Vantage system’s auto-
sampler. Ten microliters (10 μl) of each sample, containing
1 μg total protein and 5fmol of isotopically labeled internal
standard EGFR peptide, were directly injected into the sys-
tem at a loading flow rate of 5 μl/min. Liquid Tissue lysates
were directly injected into the LC system with no proces-
sing because the proprietary buffer contains no components
that may interfere with chromatography or suppress
ionization. Direct injection of Liquid Tissue lysates has been
demonstrated in multiple reports and across different mass
spectrometry platforms [14-20].
Peptide separations were performed on an nano-
AcquityLC system (Waters, Milford, MA) or EASY-nLC
II (Thermo Scientific, San Jose, CA) with a PicoFrit
(100 μm ID/10μm tip ID, New Objective) column self-
packed to a bed length of 12 cm with Jupiter Proteo 90Å
C12, 4 μm resin (Phenomenex, Torrance, CA). Peptides
were eluted over a 12 min gradient from 1 % to 50 %
acetonitrile, containing 0.1 % formic acid and at a flow
rate of 800 nL/min. The eluted peptides were directed
into the nanospray source of the mass spectrometer. All
acquisition methods used the following parameters: a
spray voltage of 2200 V, capillary temperature of 270°C,
10 ms of dwell time, Q1 FWHM of 0.2 and Q3 FWHM
of 0.7. All study samples were processed in triplicate.
Mass spectrometry data was analyzed by Pinpoint1.0
and/or Xcalibur2.1.
Statistical methods
Area Under Curve (AUC) for the endogenous peptide
and AUC of the isotopically labeled internal standard
peptide were used to calculate peptide quantity and the
data collated by Excel. The concentration of endogenous
EGFR peptide that results from processing of cells/tissue
with the Liquid Tissue protocol and reagents for each
sample was calculated using the following formula:
AUC Endogenous peptide
AUC isotopically labeled peptideð Þ
 amol isotopically labeled peptideð Þ
μg protein analyzed
¼ amol EGFR peptide per μg of tissue proteinQuantitation of EGFR peptide was normalized across all
samples based on the total amount of protein analyzed in a
given sample, and not the number of cells analyzed. Cell
counts were approximated but may not be counted accur-
ately during tissue microdissection, thus the uncertainty
and inability to quantitate total cellular content from FFPE.
All correlation curves and linear regression values were
developed in Excel for both ELISA immunoassay and SRM
assay, and also for comparisons between ELISA and SRM.
Results
Immunoanalysis of non-fixed cells
Four (4) tissue culture cell lines suspected of expressing
EGFR were analyzed by immunoassay to provide quanti-
tative benchmarks to experimentally assess the ability of
the mass spectrometry-based SRM assay for the EGFR
protein (EGFR-SRM assay) to precisely reflect the
amount of total EGFR protein per μg of total protein in
formalin fixed biological samples. Cells were grown in
culture, fresh protein lysates prepared, and ELISA-based
sandwich immunoassay performed to develop quantita-
tive data for the EGFR protein utilizing established meth-
odology directly in known samples.
A standard curve was prepared utilizing purified recom-
binant EGFR protein to allow for quantitation of EGFR.
The EGFR standards were assayed in triplicate with good
reproducibility (%CV range: 5.0 to 31.8) across serial
dilutions that ranged in concentration from 15.6 pg/well
(0.081 pg) in assay dilution buffer to 250 pg/well (0.891 pg)
in assay dilution buffer (Figure 1A). The linear regression
line was plotted as ELISA signal versus pg/well of
EGFR protein standard and shows a high degree of
linearity (R2 = 0.9869) indicating a curve against which
ELISA assay data can be plotted to determine quanti-
tative measure of the EGFR protein in lysates from
the non-formalin fixed cultured cells (Figure 1B).
For analysis of the non-fixed cells, 0.1 μg of protein
lysate from each of the 4 cell lines was analyzed in tripli-
cate in the EGFR ELISA immunoassay and quantitative
EGFR determined for each lysate by comparison to the
standard curve. Results indicate a range of EGFR expres-
sion from not detected (ND) in MCF7 cells to 407 pg/μg
total protein analyzed in A431 cells (Figure 1C). Bar
graph analysis demonstrates the range of EGFR expres-
sion levels which provides for an excellent set of cell
lines to compare SRM analysis of formalin fixed cells dir-
ectly to this ELISA data of the matching non-fixed cell
line preparations (Figure 1D).
These results demonstrate quantitative measurement
of EGFR levels utilizing standard immunoassay across a
collection of fresh, unfixed cell lines and establish a data-
set that can be used to determine the ability of SRM
methodology to measure the EGFR protein directly in
the matching formalin fixed cells, and to demonstrate
Figure 1 Quantitative analysis of the epidermal growth factor receptor (EGFR) protein by enzyme-linked immunosorbent assay (ELISA)
sandwich immunoassay in cultured cell lines as a basis for comparison with the mass spectrometry-based Selected Reaction
Monitoring (SRM) analysis. (A) Serial dilutions of a recombinant EGFR standard analyzed in triplicate by ELISA to establish a quantitative curve
for comparison with EGFR levels from cell lines. (B) Plot of these data on a linear regression curve (R2 = 0.9869) (C) ELISA immunoanalysis of EGFR
from protein lysates from non-fixed cells derived from 4 cell lines. (D) Plot of these data on a bar graph demonstrating a quantitative range of
EGFR protein in the cell lines. CV = coefficient of variance.
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the amount of total EGFR protein in formalin fixed cells.SRM assay development
The EGFR-SRM assay was developed in a stepwise fashion.
Purified recombinant protein was trypsinized and peptides
analyzed by Orbitrap and TSQVantage triplequadrupole
mass spectrometry to evaluate all peptides and establish a
list of candidates for absolute quantitation. Further narrow-
ing of the candidates was achieved by focusing on candidate
peptides in a TSQVantage analysis of a Liquid Tissue lysate
prepared from formalin fixed EGFR-expressing A431 tissue
culture cells. This stepwise process led to selection of a sin-
gle EGFR tryptic peptide, IPLENLQIIR, which gave the best
intensity in both trypsin digested recombinant EGFR and
fixed A431 cells as well as reproducible transition ion ratios.
The isotopically labeled internal standard synthetic peptide
and the unlabeled synthetic peptide were used to build a
standard curve against the background of the non-human,
complex, tryptic peptide mixture from P. furiosus. The
standard curve was developed such that the ratio of un-
labeled:labeled peptides are plotted against increasing
amounts of unlabeled peptide as measured against a con-
stant 5fmol amount of the isotopically labeled internalstandard peptide. Results indicate the limit of quantitation
(LOQ) at 62amol on column, limit of detection (LOD) at
31amol on column, linear regression of R2 = 0.9994, and
CVs ranging from 3.13 % to 15.81 % (Figure 2A). Achieving
low attomolar LOD/LOQ values, tight linear regression,
and minimal variation against a complex tryptic peptide
mixture indicates development of a sensitive, highly repro-
ducible, quantitative Liquid Tissue-SRM assay displaying
100% protein specificity for quantitation of this EGFR pep-
tide in a complex biological sample.SRM analysis of fixed cells and correlation to
immunoassay
The EGFR-SRM assay was performed on parallel cell cul-
tures that were formalin fixed and paraffin embedded in
order to establish the validity of the SRM assay and to
demonstrate that this assay can precisely measure EGFR
protein levels in formalin fixed samples. FFPE cell lines
were processed in the same manner as FFPE tissue (micro-
dissection and Liquid Tissue preparation) in order to repli-
cate the steps involved in SRM analysis of FFPE tumor
tissue. SRM analyses of FFPE cell lines were performed in
triplicate and data was compared for quantitative purposes
to the standard curve generated as described above
Figure 2 Analysis of EGFR using mass spectrometry-based SRM (EGFR-SRM) of Liquid Tissue lysates from the formalin fixed paraffin
embedded (FFPE) culture cells compared with ELISA analysis for EGFR from matching non-fixed cells. (A) Standard SRM curve generated
using unlabeled and isotopically labeled synthetic peptide that is used to define the limit of detection (LOD, 31 amol), define the limit of
quantitation (LOQ, 62amol), and determine the linearity of the assay (R2 = 0.9994). (B) Triplicate EGFR-SRM analysis of Liquid Tissue lysates from
formalin fixed cells. Quantitative data is reflected in amol/μg total protein. (C) Bar graph analysis of EGFR-SRM data. (D) Linear regression curve
demonstrating correlation (R2 = 0.9991) between quantitative EGFR as determined by ELISA (EGFR-ELISA) analysis of non-fixed cells and
quantitative EGFR-SRM analysis of the matching formalin fixed cells. SD = standard deviation.
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IPLENLQIIR peptide detected per μg of total protein of
Liquid Tissue lysate analyzed. Results demonstrate a range
from ND in MCF7 cells to a high of 7,106amol/μg in A431
cells with a range in CVs from 4.3 % to 21.7 % (Figure 2B).
As demonstrated by ELISA analysis of the non-fixed cul-
tures, bar graph analysis of SRM data of the matched for-
malin fixed cells indicates a range of EGFR expression
levels, suggesting high correlation of SRM analysis of for-
malin fixed cells to ELISA data from parallel-processed
fresh, unfixed cells (Figure 2C).
Analytical comparison of the ELISA immunoassay to the
SRM method was performed on a correlation curve. SRM
data (amol/μg total protein) of formalin fixed cell lines were
plotted against ELISA data (pg/μg total protein) of match-
ing non-fixed culture cells. The response curve shows a
high degree of correlation with a linear regression value of
R2 = 0.9991 (Figure 2D). These results demonstrate the Li-
quid Tissue-SRM technology platform reproduciblyquantitates levels of a single EGFR peptide in formalin fixed
cells and that the measured levels are highly correlated to
immunoassay of EGFR protein in matching cultures of
non-fixed cells. Thus, the SRM assay of EGFR reliably and
precisely reflects levels of the EGFR protein in formalin
fixed cultured cells. Development of a reliable and reprodu-
cible quantitative assay for an EGFR peptide that accurately
reflects EGFR protein levels in both non-fixed and formalin
fixed biological samples strongly suggests quantitation of
this peptide directly in FFPE tumor tissue will accurately re-
flect EGFR protein levels in clinical specimens of FFPE
tumor tissue.
SRM Analysis of Xenograft Tumors
A collection of FFPE human xenograft tumors of NSCLC
origin (n = 10) were analyzed by the EGFR-SRM assay.
Tissues from this collection display histological subtypes,
different patterns of cellular differentiation, and varying
levels of EGFR expression as previously determined by
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of frozen matching tumor tissue, and SRM of frozen
matching tissue thus providing a unique set of FFPE
tumor samples with known EGFR status [21]. Xenograft
tumors were sectioned onto DIRECTOR slides, tumor
cells microdissected to isolate human tumor cells from
mouse tissue, Liquid Tissue lysates prepared, and lysates
analyzed by SRM in triplicate. Results indicate quantita-
tion of a broad range of the EGFR peptide from
305amol/μg to 12,860amol/μg protein (>200X LOQ)
with variation ranging from CV = 0.2 % to 40 % (Table 1).
Comparing SRM data to the previous EGFR analyses indi-
cates SRM results consistent with both western blot and
SRM analysis of the matched frozen tumor tissue and show
a correlative trend to IHC data of the FFPE tumors [21].
These results demonstrate SRM application directly in
known EGFR-positive FFPE tumor tissue and further sug-
gest capability to quantify the EGFR protein directly in
FFPE tumor tissue.
SRM analysis of NSCLC patient tissue
A collection of twenty-three (23) NSCLC patient tumor
tissue samples from a phase II clinical trial was analyzed by
the EGFR-SRM assay in order to demonstrate clinical valid-
ation of the assay directly in resected tissue from patients
treated with an EGFR inhibitor and whose tumors are
historically driven by the EGFR protein. Tissues were sec-
tioned, cancerous cells microdissected, Liquid Tissue lysates
prepared, and lysates analyzed in triplicate by SRM. Results
demonstrate various quantitative levels of the EGFR peptide
in patient tumor tissue samples with a broad range from
ND to 660.73amol/μg (10X LOQ) with variation ranging
from CV= 0.77 % to 35.38 % (Figure 3). Automated quanti-
tation of three (3) tumor samples showed levels of EGFRTable 1 EGFR-SRM analysis of formalin-fixed paraffin-
embedded (FFPE) human xenograft tissue of non-small









ADC1 Adeno Moderate 2,113 9.6
ADC2 Adeno Poor 3,378 4.6
ADC3 Adeno Moderate 5,591 9.6
ADC4 Adeno Poor 305 10.9
ADC5 Adeno Poor 312 9.2
SCC1 Squamous Well 467 0.2
SCC2 Squamous Well 826 0.2
SCC3 Squamous Moderate 12,860 0.3
SCC4 Squamous Poor 757 40
SCC5 Squamous Moderate 1,736 1.4
Results are standardized to total amount of protein. SRM analysis is consistent
with previously published western blot, immunohistochemistry (IHC), and SRM
analysis of the matched frozen xenograft tissue [21].which were below the LOQ as defined by the standard
curve in P. furiosus complex proteomic matrix. Analysis of
these patient samples demonstrates a large dynamic range
within patient tissue suggesting real potential for this assay
to be clinically useful. These results demonstrate measure-
ment of EGFR directly in patient tumor tissue utilizing an
assay that has demonstrated ability to accurately measure
EGFR protein levels in formalin fixed tissue for use in im-
proving clinical decisions about EGFR-targeted therapy.
Discussion
This report describes the development of a highly sensitive
mass spectrometry-based Selected Reaction Monitoring
(SRM) assay capable of quantifying an important cancer
drug target directly in formalin fixed paraffin embedded
(FFPE) patient tumor tissue in a linear fashion across a large
range of concentrations. In conjunction with standard
pathological approaches, this assay can be used as a com-
plementary or companion diagnostic to analyze clinical
tumor specimens to support development of novel cancer
therapies or to optimize patient selection for therapies cur-
rently in use. Companion diagnostics facilitate identification
of patients likely to respond to drugs based on individual
molecular profiles which allow customization of treatment,
and thus, minimization of the risk of adverse reactions
while maximizing the effect of properly administered drugs.
Examples of successful therapeutics linked to companion
diagnostic tests include Herceptin and Gleevec [23,24].
The EGFR protein is an important therapeutic target for
cancer. Several FDA-approved therapeutic agents target the
EGFR protein. A routine, standardized clinical method,
however, has not yet been implemented, which can stratify
patients by quantitative EGFR protein expression levels in
relation to a projected benefit to EGFR-targeted therapies.
The first step on this path is to start to precisely and reliably
quantitate tumor expression of EGFR as a means of deter-
mining whose tumors express therapeutically-responsive
levels of the EGFR protein.
Currently accepted methodology to analyze protein ex-
pression in standard, formalin fixed patient tissue is limited
to immunohistochemistry (IHC), which provides visual
cellular context, but suffers from numerous drawbacks in-
cluding antibody specificity, low sensitivity, lack of objective
quantitation, inter-laboratory methodology/analytical vari-
ability, lack of inter-laboratory standardization, and inability
to multiplex biomarker analysis for high content analysis
[25-30]. As such, a protein assay technology platform for
application to formalin fixed patient tissue that overcomes
these limitations is warranted. Mass spectrometry, and spe-
cifically selected reaction monitoring method as applied by
triplequadrupole instrumentation, can provide for protein
assays with high sensitivity, absolute specificity, objective
quantitation, and multiplex capabilities [8-12]. The Liquid
Tissue-SRM diagnostic technology platform utilizes selected
Figure 3 SRM analysis for EGFR in FFPE tumor specimens taken from patients with non-small cell lung carcinoma (NSCLC) after
treatment with the EGFR inhibitor gefitinib in the neoadjuvant setting. SRM analysis across a cohort of formalin fixed tumor specimens
demonstrates EGFR quantitation across a broad range of EGFR expression levels after treatment with gefitinib.
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nostic assays for use directly on formalin fixed patient
tissue. The key to this platform is the Liquid Tissue
protocol allowing FFPE tissue to be completely solublized
resulting in a complex mixture of protease-digested pep-
tides suitable for quantitative mass spectrometry [13,14].
Protein matter within tissue is preserved by formalin fix-
ation due to the fact that intra- and intermolecular cross-
links are formed by formalin treatment effectively
stabilizing all proteins, suspending enzymatic activity and
preventing destruction [31]. Further, embedding in paraffin
effectively removes all water from the tissue thereby
allowing the tissue to be stored at room temperature for
years with minimal deterioration. It has been shown, how-
ever, in a model system based on formalin fixation that
enzyme activity and antigenicity of RNAse can be restored
by extensive heating showing that this protein has been well
preserved within formalin fixed tissue, and that widespread
protein deterioration has not occurred [32-34]. Formalin
fixation also reduces antigenicity of proteins within tissue
due to cross linking and this is an important consideration
when using antibodies to detect proteins in fixed tissues. It
should be noted that optimization of antigen retrieval is es-
sential to utilize antibody-based methods to identify pro-
teins from formalin fixed tissue. This approach is especially
important for standardizing immunohistochemical methods
across labs and for attempting to multiplex IHC in fixed
tissue.
The Liquid Tissue process is based on heat retrieval of
proteins present in tissue followed by protease digestion.
Placing formalin fixed tissue/cells in a buffer followed by
extended heating at elevated temperature has two effects:1) reversal of formalin-induced crosslinks, and 2) re-
moval of secondary/tertiary/quaternary protein structure
to allow for protease digestion of the primary protein
structure. While obtaining information from the
expanded protein structure is important in many studies,
the Liquid Tissue process is deducing information from
the primary protein structure by analyzing peptide frag-
ments only, and any lack of information about second-
ary/tertiary/quaternary structure does not impede the
powerful advancement that the Liquid Tissue protocol
and reagents afford. This methodology utilizes patient
tissue that has been prepared using standard histopath-
ology methodology and, as such, represents a powerful
advance translatable to clinical research.
Multiple reports have demonstrated mass spectromet-
ric analysis of formalin fixed tissue and these studies
show comparable results are obtained between formalin
fixed and matching frozen tissue [14,35-38]. When com-
bined with tissue microdissection for collection of spe-
cific diseased cell populations the resulting Liquid Tissue
lysate represents the molecular histology/profile of the
disease where expression of proteins associated with the
disease process can be monitored.
This platform was used to develop a quantitative assay for
the EGFR protein in FFPE tissue samples taken from
patients with NSCLC enrolled in a phase II neoadjuvant
trial of the EGFR inhibitor, gefitinib. Assay performance was
demonstrated on cell culture models of formalin fixed tissue
indicating the ability to accurately measure levels of the
EGFR protein directly in formalin fixed samples across a
wide range of EGFR concentrations. The reliability of this
analytical approach was demonstrated by application of this
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ability to measure EGFR protein levels was demonstrated to
be consistent with previously-determined EGFR levels in
these samples. The application of this assay to a cohort of
FFPE tissues surgically resected from NSCLC patients that
participated in an EGFR-targeted therapeutic trial indicates
its ability to monitor EGFR levels directly in patient-derived
tumor tissue.
Potential applications of this assay include the ability
to identify cancer patients that would benefit from
EGFR-inhibitor therapies and may indicate a mode of
drug resistance for growth factor receptor-targeted ther-
apies where a “kinase switch” mechanism for acquired
resistance to IGF-1R and cMet inhibition results from
co-expression of EGFR in the cancer cells. Combining
the current EGFR assay in a multiplex fashion with simi-
lar assays for IGF-1R and cMet could provide for optimal
therapeutic choice and a drug resistance biomarker panel
to drive targeted therapeutic efforts in NSCLC, as well as
other cancers.
This EGFR-SRM assay represents a highly promising
approach to quantitating and monitoring EGFR levels in
patient tumor tissue. Immuno-based methods, such as
western blot and ELISA, cannot be effectively performed
on FFPE patient tissue due to formalin-induced cross-
linking, and IHC methods struggle to achieve specificity,
reliability and reproducibility. Reports have demon-
strated analysis of protein from formalin fixed tissue
using western blot. These approaches, however, suffer
from lack of total representation because all protein is
not solubilized prior to gel separation and the majority
of proteins detected by western blot are limited to highly
abundant proteins [39,40]. Because the Liquid Tissue
protocol generates protease-digested peptides from for-
malin fixed tissue, it cannot be used for preparing sample
for ELISA and/or western blot.
SRM methodology provides a quantitative, sensitive,
and reproducible approach for analysis of proteins in any
biological sample and this report demonstrates the appli-
cation of SRM methodology to measuring EGFR protein
levels in FFPE biological samples, including patient
tumor tissue. Experiments to establish clinical utility of
this assay for patient stratification, choice of therapy, and
drug resistance prediction are ongoing and will be an im-
portant next step in developing companion diagnostic
assays for EGFR-targeted therapy.Abbreviations
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